Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874259 | 0.87 | CYP2D6 (0.41) | CYP2D6CYP2C19TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL6722031 | 0.82 | CYP2D6 (0.44) | CYP2D6CYP2C19TSHRCHRNB2CHRNB4 | |
| SCHEMBL28850928 | 0.80 | CYP2D6 (0.43) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL667964 | 0.78 | — | — | |
| SCHEMBL7465098 | 0.77 | ECE1 (0.42) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL5933309 | 0.77 | CYP2D6 (0.40) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL13268513 | 0.76 | — | — | |
| SCHEMBL1261996 | 0.76 | — | — | |
| SCHEMBL4578261 | 0.76 | CYP2D6 (0.37) | CYP2D6CYP2C19ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL1923786 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1503749-A4 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARM INC (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008011114-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1503749-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | Praecis Pharmaceuticals Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003092608-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1330447-A2 | PEPTIDES AS MET-AP2 INHIBITORS | Praecis Pharmaceuticals Incorporated (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002042295-A2 | PEPTIDES AS MET-AP2 INHIBITORS | PRAECIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | CYP2D6 3974/4885CYP2C19 3729/4885TSHR 3185/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | CYP2D6 3974/4885CYP2C19 3729/4885TSHR 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.